Document is current
Any future updates will be listed below
-
Authors
Goethals, Olivia https://orcid.org/0000-0001-8214-8989
Kaptein, Suzanne J. F. https://orcid.org/0000-0002-7935-0219
Kesteleyn, Bart https://orcid.org/0000-0003-3862-4153
Bonfanti, Jean-François https://orcid.org/0000-0002-2107-8857
Van Wesenbeeck, Liesbeth
Bardiot, Dorothée
Verschoor, Ernst J. https://orcid.org/0000-0003-0912-2074
Verstrepen, Babs E. https://orcid.org/0000-0002-4666-0798
Fagrouch, Zahra
Putnak, J. Robert
Kiemel, Dominik
Ackaert, Oliver https://orcid.org/0000-0002-5908-5200
Straetemans, Roel
Lachau-Durand, Sophie
Geluykens, Peggy
Crabbe, Marjolein
Thys, Kim
Stoops, Bart
Lenz, Oliver
Tambuyzer, Lotke https://orcid.org/0000-0002-1705-3753
De Meyer, Sandra
Dallmeier, Kai https://orcid.org/0000-0002-8117-9166
McCracken, Michael K.
Gromowski, Gregory D.
Rutvisuttinunt, Wiriya
Jarman, Richard G. https://orcid.org/0000-0002-5765-0173
Karasavvas, Nicos
Touret, Franck https://orcid.org/0000-0002-4734-2249
Querat, Gilles
de Lamballerie, Xavier https://orcid.org/0000-0001-7895-2720
Chatel-Chaix, Laurent https://orcid.org/0000-0002-7390-8250
Milligan, Gregg N.
Beasley, David W. C.
Bourne, Nigel
Barrett, Alan D. T.
Marchand, Arnaud
Jonckers, Tim H. M.
Raboisson, Pierre
Simmen, Kenny
Chaltin, Patrick
Bartenschlager, Ralf https://orcid.org/0000-0001-5601-9307
Bogers, Willy M. https://orcid.org/0000-0002-4563-8513
Neyts, Johan https://orcid.org/0000-0002-0033-7514
Van Loock, Marnix https://orcid.org/0000-0003-4151-4588
- License Information
-
More Information
Article History
Received: 29 June 2022
Accepted: 3 February 2023
First Online: 15 March 2023
Competing interests
: B.K., J.-F.B., T.H.M.J., P.R., D.B. and A.M. have been named inventors in a patent application claiming the discovery of this class of antiviral molecules as DENV replication inhibitors (WO 2016/180696), which was filed by Applicants Janssen Pharmaceuticals, Inc. and Katholieke Universiteit Leuven, and has been granted in certain countries. O.G., B.K., B.S., J.-F.B., T.H.M.J., M.V.L., S.J.F.K. and J.N. have been named inventors in a pending patent application relating to the use of substituted indole derivatives and substituted indoline derivatives in the manufacture of a medicament for the treatment or the prevention of dengue disease in an individual at risk of being infected by DENV and to a method for the treatment or the prevention of dengue in an individual at risk of being infected by DENV, which was filed by Applicants Janssen Pharmaceuticals, Inc. and Katholieke Universiteit Leuven (WO 2021/094563). O.G., B.K., L.V.W., O.A., R.S., S.L.-D., M.C., K.T., B.S., O.L., L.T., S.D.M., T.H.M.J., K.S. and M.V.L. are all full-time employees of Janssen and potential stockholders of Johnson and Johnson. The other authors declare no competing interests.
